Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD1VZL)

• Drug Name: Pemafibrate Drug Info
• Synonyms: K-877

Indication

Disease Entry	ICD 11	Status	REF
Hyperlipidemia	5C80.Z	Approved	[1]
Cardiovascular disease	BA00-BE2Z	Phase 3	[2]
Lipid metabolism disorder	5C52.Z	Phase 3	[3]

• Cross-matching ID:
  PubChem CID: 11526038
  CAS Number: CAS 848259-27-8
  TTD Drug ID: DMD1VZL

Molecule-Related Drug Atlas

Drug(s) Targeting Peroxisome proliferator-activated receptor alpha (PPARA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lobeglitazone	DMHY3IP	Type-2 diabetes	5A11	Approved	[4]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[5]
Bezafibrate	DMZDCS0	Hypercholesterolaemia	5C80.0	Approved	[6]
Ciprofibrate	DMGC5DB	Hyperlipoproteinemia	5C80	Approved	[5]
MURAGLITAZAR	DMG3NFZ	N. A.	N. A.	Phase 3	[7]
Ragaglitazar	DMFSHEM	Type-1 diabetes	5A10	Phase 3	[8]
CS-038	DM67P0F	Type-2 diabetes	5A11	Phase 3	[9]
TESAGLITAZAR	DMGRBN5	Type-1 diabetes	5A10	Phase 3	[10]
GFT-505	DM7ZOAE	Non-alcoholic steatohepatitis	DB92.1	Phase 3	[11]
ZYH-1	DMMBJYC	Lipid metabolism disorder	5C52.Z	Phase 3	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Peroxisome proliferator-activated receptor alpha (PPARA)	TTJ584C	PPARA_HUMAN	Agonist	[1]

References

• [1] Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032781)
• [4] Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
• [5] Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
• [6] Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
• [7] Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
• [8] Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
• [9] Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
• [10] Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
• [11] Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
• [12] Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.